Novo Nordisk China

Novo Nordisk is a world-leading biopharmaceutical company, holding a top global position in the development and production of insulin for diabetes treatment. Novo Nordisk was the first to introduce long-acting insulin, pre-mixed insulin, highly purified insulin, human insulin, and insulin injection pens. Additionally, Novo Nordisk pioneered a new class of oral hypoglycemic drugs - NovoLog, significantly enhancing the level of diabetes treatment and control and improving the quality of life for people with diabetes. Moreover, Novo Nordisk holds leading positions worldwide in many areas such as coagulation therapy, growth care, and hormone replacement therapy. Its subsidiary, Diabetes Doctors Network, is a professional website for diabetes specialists, providing online learning materials, access to numerous case analyses, exchanges with experts across China, coverage of major domestic and international medical conferences, and updates on diabetes academic progress. The company also offers diabetes education to help patients improve their lifestyle.